Abstract Search

ea0092ps1-06-08 | Thyroid Cancer clinical 1 | ETA2023

Hypertension during lenvatinib for advanced thyroid cancer: a diagnostic and therapeutic algorithm for its management

Daniele Ceruti , Carla Colombo , Leo Simone De , Grzegorz Bilo , Matteo Trevisan , Noemi Giancola , Claudia Moneta , Gianfranco Parati , Luca Persani , Laura Fugazzola

Background: Hypertension (HTN) is the most frequent adverse event during treatment with Lenvatinib (LEN) for advanced Radioactive Iodine-Resistant Thyroid Cancer (RAI-R TC), but data on its best therapeutic management are limited.Objectives: To assess incidence, features and best management of LEN-related HTN in a consecutive single tertiary-care Centre.Methods: Evaluation included 29 patients treated with LEN, followed for a mean ...

0 shares

ea0035p1126 | Thyroid Cancer | ECE2014

TERT promoter mutations correlate with a more advanced stage at diagnosis and with a poorer prognosis in differentiated thyroid cancer

Colombo Carla , Muzza Marina , Rossi Stefania , Cirello Valentina , Perrino Michela , Tosi Delfina , Vigo Beatrice , Leo Simone De , Bulfamante Gaetano , Magnani Elisa , Pignatti Elisa , Simoni Manuela , Vicentini Leonardo , Fugazzola Laura

Telomerase is a ribonucleoprotein polymerase that maintains telomere ends and plays a role in cellular senescence, being repressed in postnatal somatic cells. Mutations C228T and C250T of the telomerase reverse transcriptase (TERT) were recently reported in human cancers. In thyroid cancer, TERT mutations are more frequent in aggressive histotypes, but very few data are available about the potential correlations with clinical features in papillary and follicular thyroid cancer...

0 shares

ePoster

Endocrine Abstracts

Hypertension during lenvatinib for advanced thyroid cancer: a diagnostic and therapeutic algorithm for its management

TERT promoter mutations correlate with a more advanced stage at diagnosis and with a poorer prognosis in differentiated thyroid cancer

BiosciAbstracts